...
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Effects of indapamide, a thiazide-like diuretic, on structure of cerebral arterioles in hypertensive rats.
【24h】

Effects of indapamide, a thiazide-like diuretic, on structure of cerebral arterioles in hypertensive rats.

机译:噻嗪类利尿剂吲达帕胺对高血压大鼠脑小动脉结构的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

We examined the effects of indapamide, a thiazide-like diuretic, on cerebral arterioles in spontaneously hypertensive rats (SHR). The structure and mechanics of cerebral arterioles were examined in untreated Wistar Kyoto rats (WKY) and SHR that were untreated or treated for 3 months with a low (1 mg/kg per day) or a high (10 mg/kg per day) dose of indapamide. We measured pressure, diameter, and cross-sectional area of the vessel wall (CSA) in maximally-dilated (EDTA) cerebral arterioles. Treatment of SHR with the high dose of indapamide normalized cerebral arteriolar mean pressure (62+/-4 [mean+/-SEM] versus 59+/-3 mm Hg in WKY and 88+/-6 mm Hg in untreated SHR; P<0.05), pulse pressure (13+/-1 versus 10+/-1 mm Hg in WKY and 20+/-1 mm Hg in untreated SHR; P<0.05), and CSA (1080+/-91 versus 1100+/-48 microm2 in WKY and 1439+/-40 microm2 in untreated SHR; P<0.05). In contrast, treatment of SHR with the low dose of indapamide did not normalize arteriolar mean (72+/-3) and pulse pressure (20+/-1 mm Hg), butdid normalize CSA (1091+/-52 microm2). Treatment with either dose of indapamide failed to increase external diameter in cerebral arterioles of SHR (89+/-4 and 92+/-4 microm, respectively, versus 103+/-6 microm in WKY and 87+/-4 microm in untreated SHR). Finally, treatment with indapamide attenuated the rightward shift of the stress-strain curve in SHR, suggesting that treatment with indapamide attenuated increases in distensibility of cerebral arterioles in SHR. These findings suggest that, whereas thiazide-like diuretics may not attenuate eutrophic inward remodeling of cerebral arterioles in SHR, they may attenuate hypertrophic inward remodeling via a mechanism unrelated to their pressor effects.
机译:我们检查了吲哚帕胺(一种噻嗪类利尿剂)对自发性高血压大鼠(SHR)脑小动脉的影响。在未经治疗的Wistar Kyoto大鼠(WKY)和SHR中对脑小动脉的结构和力学进行了检查,这些大鼠未经治疗或以低剂量(每天1 mg / kg)或高剂量(每天10 mg / kg)治疗3个月吲达帕胺。我们测量了最大扩张的(EDTA)脑小动脉中血管壁(CSA)的压力,直径和横截面积。用高剂量的吲达帕胺标准化的脑小动脉平均压力(62 +/- 4 [mean +/- SEM]相对于WKY中的59 +/- 3 mm Hg和未治疗的SHR中的88 +/- 6 mm Hg,对SHR进行治疗; P < 0.05),脉压(WKY中为13 +/- 1对10 +/- 1 mm Hg,未经治疗的SHR中为20 +/- 1 mm Hg; P <0.05)和CSA(1080 +/- 91对1100 + / WKY中为-48 microm2,未经处理的SHR中为1439 +/- 40 microm2; P <0.05)。相反,用低剂量的吲达帕胺治疗SHR不能使小动脉平均(72 +/- 3)和脉压(20 +/- 1 mm Hg)正常化,而使CSA(1091 +/- 52 microm2)正常化。两种剂量的吲达帕胺治疗均未能增加SHR脑小动脉的外径(分别为89 +/- 4和92 +/- 4微米,而WKY为103 +/- 6微米,未经治疗的为87 +/- 4微米) SHR)。最后,吲达帕胺治疗减弱了SHR的应力-应变曲线的向右移动,表明吲达帕胺治疗减弱了SHR中脑小动脉的扩张性。这些发现表明,尽管噻嗪类利尿剂可能不会减弱SHR中脑小动脉的富营养性内向重塑,但它们可能通过与其升压作用无关的机制来减轻肥大性内向重塑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号